MWNA
ADCT icon

Marshall Wace North America’s ADC Therapeutics ADCT Stock Holding History

Marshall Wace North America’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,057
Closed -$962K – 1463
2020
Q4 		$962K Sell
30,057
-45,786
-60% -$1.5M ﹤0.01% 952
2020
Q3 		$2.5M Buy
75,843
+44,853
+145% +$1.94M 0.02% 531
2020
Q2 		$1.45M Buy
+30,990
New +$1.18M 0.01% 662

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Marshall Wace North America's ADCT Position: Q1 2021 in Review

Marshall Wace North America sold out of ADC Therapeutics (ADCT) in Q1 2021, closing a stake of 30,057 shares — an estimated $962K sold.

Marshall Wace North America first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $2.5M in Q3 2020. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2021.

  • Marshall Wace North America reported no remaining ADC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 30,057 ADC Therapeutics shares in Q1 2021, an estimated $962K.
  • Marshall Wace North America first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Marshall Wace North America's ADC Therapeutics position peaked at $2.5M in Q3 2020.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.